Surge In Cancer Cases Expected To Drive Growth In The Cancer Biopsy Market Driving Market Acceleration in the Cancer Biopsy Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Cancer Biopsy Market Size By 2025?
Over the years, the cancer biopsy market has been experiencing significant growth. Projections suggest that its overall worth will increase from $25.08 billion in 2024 to $28.52 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.7%. This surge during the historical period can be ascribed to various factors, including enhanced understanding of breast cancer liquid biopsy procedures as well as inherited oncology disorders and genetic testing, rising preference for liquid biopsies, heightened demand for least invasive biopsy therapies, and an increasing need for tissue biopsies.

How Big Is the Cancer Biopsy Market Size Expected to Grow by 2029?
Over the forthcoming years, the cancer biopsy market is projected to experience swift expansion, with a predicted worth of $47.2 billion in 2029, reflecting a compound annual growth rate (CAGR) of 13.4%. This anticipated surge within the forecast period can be ascribed to various factors such as the rising prevalence of patients, looming geriatric population, escalating number of patients potentially having breast cancer, augmented cases of cancer, soaring rate of diagnosis and biopsy tests, along with increased patient count. Prevailing tendencies during the forecast period are anticipated to include technological progress, implementation of artificial intelligence and machine learning, incorporation of multi-omics, product innovations and the introduction of point-of-care biopsy apparatus.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-biopsy-global-market-report

Which Key Market Drivers Powering Cancer Biopsy Market Expansion and Growth?
The surge in cancer cases is likely to boost the expansion of the cancer biopsy market in the future. Cancer, which is a complex set of diseases characterized by irregular cell growth and dissemination, has become more prevalent due to various factors. These include lifestyle modifications and urbanization, pollution, tobacco and alcohol use, access to healthcare, and increased awareness. Cancer biopsies, which involve extracting and examining tissue or cells from a potentially cancerous region, are integral in diagnosing cancer as well as determining its type, stage, and extent of spread. Citing the National Center for Biotechnology Information, a US intergovernmental organization, in January 2023, the United States reported 1,958,310 new cancer cases and 609,820 cancer-related deaths. Moreover, the National Library of Medicine, a US-based medical library, projected in May 2021 that the global cancer burden is anticipated to rise by 47% from 2020 and reach 28.4 million cases in 2040, resulting in a significant number of fatalities. Hence, the escalating prevalence of cancer is a key driving force for the cancer biopsy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19355&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Cancer Biopsy Market?
Prominent companies in the cancer biopsy market are progressing with the creation of liquid biopsy methods to enhance non-invasive, earlier cancer detection and surveillance, better patient results, and enable more personalized therapeutic strategies. Liquid biopsy, a cutting-edge and non-invasive testing method, identifies and examines genetic data from a blood sample, which includes circulating tumor DNA (ctDNA), RNA, exosomes, and additional biomarkers. For example, Labcorp, a US-manufacturing company specializing in cancer biopsies, unveiled Labcorp Plasma Focus, a liquid biopsy focused on plasma to locate cancer-related biomarkers, in May 2023. Labcorp's Plasma Focus test examines circulating cell-free DNA (cfDNA) that tumor cells release into the bloodstream. It builds a genomic profile of the patient's tumor, detecting mutations in 33 genes linked to a range of cancer types such as non-small cell lung cancer, colorectal cancer, breast cancer, esophageal cancer, and melanoma.

What Are the Emerging Segments in the Cancer Biopsy Market?
The cancer biopsymarket covered in this report is segmented -

1) By Type: Tissue Biopsies, Liquid Biopsies, Other Types
2) By Application: Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Prostate Cancers, Skin Cancers, Blood Cancers, Kidney Cancers, Other Applications
3) By End User: Hospitals, Diagnostic Laboratories, Other End Users

Subsegments:
1) By Tissue Biopsies: Core Needle Biopsies, Fine Needle Aspiration (FNA) Biopsies, Incisional Biopsies, Excisional Biopsies
2) By Liquid Biopsies: Circulating Tumor Cell (CTC) Analysis, Circulating Tumor DNA (ctDNA) Testing, Plasma Biomarker Testing
3) By Other Types: Bone Biopsies, Endoscopic Biopsies, Brush Biopsies, Skin Biopsies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19355&type=smp

Who Are the Global Leaders in the Cancer Biopsy Market?
Major companies operating in the cancer biopsy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Roche Diagnostics GmbH, Hologic Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., Guardant Health Inc., Veracyte Inc., GRAIL Inc., Freenome Holdings Inc., Biodesix Inc., Chronix Biomedical Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Oncimmune Holdings plc, Exosome Diagnostics Inc., Epigenomics AG, Genesystems Inc., Lucence Diagnostics Pte. Ltd., ANGLE plc

Which are the Top Profitable Regional Markets for the Cancer Biopsy Industry?
North America was the largest region in the cancer biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19355

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.